InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（1 笔）
内部人交易记录
首席执行官已披露买入
2
已披露卖出
1
T+90 胜率
0%
T+90 平均收益
-7.9%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the full record of transactions filed by Mark Miller, Directeur Exécutif Affaires Médicales. Insider active across 1 company, notably BIOMERIEUX. In total, 4 filings have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €182k. History available since 26 February 2022. The latest transaction was disclosed on 4 September 2023 (Cession). Regulator: AMF. The full history is accessible without signup.
Companies and markets linked to Mark Miller
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
1,567 股@ €96.03281.2% 占其流量ActionEuronext ParisISIN FR00132802862023DD926508
3,625 股0ActionHors plateforme de négociationISIN FR00132802862023DD926507
300 股@ US$115.8218.8% 占其流量ActionHors plateforme de négociationISIN FR00132802862023DD916808
标准退出：2023年9月21日 (T+90)
6,052 股0ActionAcquisition d'actions gratuiteISIN FR00132802862022DD824952
标准退出：2022年5月27日 (T+90)
4 条申报中的 4 条
About Mark Miller
Mark Miller is the Executive Vice President, Chief Medical Officer at BIOMERIEUX. He oversees the medical and strategic operations of the company, playing a key role in developing diagnostic solutions. His expertise in the healthcare sector is essential for innovation and growth.
